References

The m6A modification-mediated OGDHL exerts a tumor suppressor role in ccRCC by downregulating FASN to inhibit lipid synthesis and ERK signaling

10.1038/s41419-023-06090-7 · 2023 · External reference

Renal cell carcinoma

10.1038/nrdp.2017.9 · 2017 · External reference

Renal Cell Carcinoma: A Review

10.1001/jama.2024.12848 · 2024 · External reference

USP7 depletion potentiates HIF2α degradation and inhibits clear cell renal cell carcinoma progression

10.1038/s41419-024-07136-0 · 2024 · External reference

Renal cell carcinoma

10.1136/bmj.g4797 · 2014 · External reference

European Association of Urology Guidelines on Renal Cell Carcinoma: The 2025 Update

10.1016/j.eururo.2025.02.020 · 2025 · External reference

Single-cell sequencing links multiregional immune landscapes and tissue-resident T cells in ccRCC to tumor topology and therapy efficacy

10.1016/j.ccell.2021.03.007 · 2021 · External reference

The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy

10.1038/s41568-019-0116-x · 2019 · External reference

Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab

10.1016/j.cell.2017.09.028 · 2017 · External reference

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

10.1038/nature14011 · 2014 · External reference

CILP2 promotes hypertrophic scar through Snail acetylation by interaction with ACLY

10.1016/j.bbadis.2024.167202 · 2024 · External reference

Cartilage intermediate layer protein 2 (CILP-2) is expressed in articular and meniscal cartilage and down-regulated in experimental osteoarthritis

10.1074/jbc.m111.248039 · 2011 · External reference

Fibrotic-like changes in degenerate human intervertebral discs revealed by quantitative proteomic analysis

10.1016/j.joca.2015.09.020 · 2016 · External reference

Changes in the chondrocyte and extracellular matrix proteome during post-natal mouse cartilage development

10.1074/mcp.m111.014159 · 2012 · External reference

The Interplay between Extracellular Matrix Remodeling and Cancer Therapeutics

10.1158/2159-8290.cd-24-0002 · 2024 · External reference

Extracellular matrix remodeling facilitates obesity-associated cancer progression

10.1016/j.tcb.2022.02.008 · 2022 · External reference

CILP2: A prognostic biomarker associated with immune infiltration in colorectal cancer

2023 · External reference

CILP, a Putative Gene Associated With Immune Infiltration in Breast Cancer Brain Metastases

2022 · External reference

CILP2 is a potential biomarker for the prediction and therapeutic target of peritoneal metastases in colorectal cancer

10.1038/s41598-024-63366-4 · 2024 · External reference

FOXM1: A small fox that makes more tracks for cancer progression and metastasis

10.1016/j.semcancer.2023.03.007 · 2023 · External reference

Dysregulated FOXM1 signaling in the regulation of cancer stem cells

10.1016/j.semcancer.2022.07.009 · 2022 · External reference

Transcription factor FOXM1 specifies chromatin DNA to extracellular vesicles

10.1080/15548627.2023.2284523 · 2024 · External reference

Targeting FOXM1 in cancer

10.1016/j.bcp.2012.10.013 · 2013 · External reference

FOXM1: A key oncofoetal transcription factor in health and disease

10.1016/j.semcancer.2014.07.008 · 2014 · External reference

FOXM1 facilitates breast cancer cell stemness and migration in YAP1-dependent manner

10.1016/j.abb.2020.108349 · 2020 · External reference

Updates in the Eighth Edition of the Tumor-Node-Metastasis Staging Classification for Urologic Cancers

10.1016/j.eururo.2017.12.018 · 2018 · External reference

CTCF-activated FUCA1 functions as a tumor suppressor by promoting autophagy flux and serum α-L-fucosidase serves as a potential biomarker for prognosis in ccRCC

10.1186/s12935-024-03502-2 · 2024 · External reference

Integrated molecular analysis of clear-cell renal cell carcinoma

10.1038/ng.2699 · 2013 · External reference

Robust enumeration of cell subsets from tissue expression profiles

10.1038/nmeth.3337 · 2015 · External reference

Tumor immune dysfunction and exclusion subtypes in bladder cancer and pan-cancer: a novel molecular subtyping strategy and immunotherapeutic prediction model

10.1186/s12967-024-05186-8 · 2024 · External reference

The Prognostic and Immune Significance of CILP2 in Pan-Cancer and Its Relationship with the Progression of Pancreatic Cancer

10.3390/cancers15245842 · 2023 · External reference

Alternative splicing in EMT and TGF-β signaling during cancer progression

10.1016/j.semcancer.2024.04.001 · 2024 · External reference

Classical epithelial-mesenchymal transition (EMT) and alternative cell death process-driven blebbishield metastatic-witch (BMW) pathways to cancer metastasis

10.1038/s41392-022-01132-6 · 2022 · External reference

Hypoxia-induced epithelial to mesenchymal transition in cancer

10.1016/j.canlet.2020.05.012 · 2020 · External reference

Luteolin suppresses androgen receptor-positive triple-negative breast cancer cell proliferation and metastasis by epigenetic regulation of MMP9 expression via the AKT/mTOR signaling pathway

10.1016/j.phymed.2020.153437 · 2021 · External reference

Visualizing Epithelial-Mesenchymal Transition Using the Chromobody Technology

10.1158/0008-5472.can-15-3419 · 2016 · External reference

Small-molecule inhibitors targeting FOXM1: Current challenges and future perspectives in cancer treatments

10.1016/j.bbcan.2023.189015 · 2023 · External reference

Bile acids activate cancer-associated fibroblasts and induce an immunosuppressive microenvironment in cholangiocarcinoma

10.1016/j.ccell.2025.05.017 · 2025 · External reference

CAFs secreted exosomes promote metastasis and chemotherapy resistance by enhancing cell stemness and epithelial-mesenchymal transition in colorectal cancer

10.1186/s12943-019-1019-x · 2019 · External reference

TGF-β in developmental and fibrogenic EMTs

2022 · External reference